StockData
VivoSim Labs, INC. logo

VivoSim Labs, INC. (VIVS) stock

VIVSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$0.12−0.00 (-2.91%)

Close on Nov 17, 2026Market cap $383.64KP/E –Yield –

VivoSim Labs gross margin

Gross margin is gross profit as a percentage of revenue.

VivoSim Labs's gross margin for the twelve months ending Mar 31, 2026 was 100.0%. For fiscal 2026 it was 100.0%, against 96.5% the year before. The highest annual figure on record is 100.0% in fiscal 2015.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2026Mar 31, 2026100.0%+3.5
FY2025Mar 31, 202596.5%+10.2
FY2020Mar 31, 202086.3%+2.5
FY2019Mar 31, 201983.8%+5.5
FY2018Mar 31, 201878.3%+0.9
FY2017Mar 31, 201777.4%−22.6
FY2016Mar 31, 2016100.0%+0.0
FY2015Mar 31, 2015100.0%+12.5
FY2011Dec 31, 201187.5%–

Quarterly gross margin

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange (pts)
Q4 FY2026CQ1 2026Mar 31, 2026100.0%+0.0
Q3 FY2026CQ4 2025Dec 31, 2025100.0%+8.3
Q2 FY2026CQ3 2025Sep 30, 2025100.0%+3.3
Q1 FY2026CQ2 2025Jun 30, 2025100.0%+5.1
Q4 FY2025CQ1 2025Mar 31, 2025100.0%+0.0
Q3 FY2025CQ4 2024Dec 31, 202491.7%−8.3
Q2 FY2025CQ3 2024Sep 30, 202496.7%+1.0
Q1 FY2025CQ2 2024Jun 30, 202494.9%+19.3
Q3 FY2024CQ4 2023Dec 31, 2023100.0%+15.0
Q1 FY2024CQ2 2023Jun 30, 2023100.0%+14.7
Q3 FY2020CQ4 2019Dec 31, 201995.6%+8.5
Q2 FY2020CQ3 2019Sep 30, 201975.6%−13.8
Q1 FY2020CQ2 2019Jun 30, 201985.0%−0.5
Q4 FY2019CQ1 2019Mar 31, 201985.3%+12.4
Q3 FY2019CQ4 2018Dec 31, 201887.2%+4.5
Q2 FY2019CQ3 2018Sep 30, 201889.4%+11.5
Q1 FY2019CQ2 2018Jun 30, 201885.5%+15.8
Q4 FY2018CQ1 2018Mar 31, 201872.9%−4.6
Q3 FY2018CQ4 2017Dec 31, 201782.7%+1.1
Q2 FY2018CQ3 2017Sep 30, 201777.9%+6.4
Q1 FY2018CQ2 2017Jun 30, 201769.7%–
Q4 FY2017CQ1 2017Mar 31, 201777.5%–
Q3 FY2017CQ4 2016Dec 31, 201681.6%–
Q2 FY2017CQ3 2016Sep 30, 201671.4%–

More VivoSim Labs figures

See a number that looks wrong?